Vemurafenib is approved for treating metastatic melanoma. It works by inhibiting the activity of BRAF, a protein which, when mutated, drives the growth of metastatic melanoma. Vemurafenib is approved specifically for adult patients with a BRAF mutation called V600. It is taken orally (by mouth).
In this study, researchers are assessing the effectiveness of vemurafenib for treating multiple myeloma and solid tumors other than melanoma which contain a BRAF V600 mutation, such as langerhans cell histiocytosis (LCH) and Erdheim-Chester Disease (ECD).